746 related articles for article (PubMed ID: 30709609)
1. The Case for Real-world Evidence in the Future of Clinical Research on Chronic Myeloid Leukemia.
Webster J; Smith BD
Clin Ther; 2019 Feb; 41(2):336-349. PubMed ID: 30709609
[TBL] [Abstract][Full Text] [Related]
2. Trial designs using real-world data: The changing landscape of the regulatory approval process.
Baumfeld Andre E; Reynolds R; Caubel P; Azoulay L; Dreyer NA
Pharmacoepidemiol Drug Saf; 2020 Oct; 29(10):1201-1212. PubMed ID: 31823482
[TBL] [Abstract][Full Text] [Related]
3. Use of real-world evidence in regulatory decisions for rare diseases in the United States-Current status and future directions.
Wu J; Wang C; Toh S; Pisa FE; Bauer L
Pharmacoepidemiol Drug Saf; 2020 Oct; 29(10):1213-1218. PubMed ID: 32003065
[TBL] [Abstract][Full Text] [Related]
4. Improving Transparency to Build Trust in Real-World Secondary Data Studies for Hypothesis Testing-Why, What, and How: Recommendations and a Road Map from the Real-World Evidence Transparency Initiative.
Orsini LS; Berger M; Crown W; Daniel G; Eichler HG; Goettsch W; Graff J; Guerino J; Jonsson P; Lederer NM; Monz B; Mullins CD; Schneeweiss S; Brunt DV; Wang SV; Willke RJ
Value Health; 2020 Sep; 23(9):1128-1136. PubMed ID: 32940229
[TBL] [Abstract][Full Text] [Related]
5. Real-world data: a comprehensive literature review on the barriers, challenges, and opportunities associated with their inclusion in the health technology assessment process.
Zisis K; Pavi E; Geitona M; Athanasakis K
J Pharm Pharm Sci; 2024; 27():12302. PubMed ID: 38481726
[No Abstract] [Full Text] [Related]
6. [Real-world evidence : Benefits and limitations in multiple sclerosis research].
Ziemssen T; Rothenbacher D; Kuhle J; Berger T
Nervenarzt; 2017 Oct; 88(10):1153-1158. PubMed ID: 28776214
[TBL] [Abstract][Full Text] [Related]
7. The Expanding Role of Real-World Evidence Trials in Health Care Decision Making.
Klonoff DC
J Diabetes Sci Technol; 2020 Jan; 14(1):174-179. PubMed ID: 30841738
[TBL] [Abstract][Full Text] [Related]
8. Dasatinib: a tyrosine kinase inhibitor for the treatment of chronic myelogenous leukemia and philadelphia chromosome-positive acute lymphoblastic leukemia.
Steinberg M
Clin Ther; 2007 Nov; 29(11):2289-308. PubMed ID: 18158072
[TBL] [Abstract][Full Text] [Related]
9. Comparison of two assessments of real-world data and real-world evidence for regulatory decision-making.
Yuan L; Rahman M; Concato J
Clin Transl Sci; 2024 Jan; 17(1):e13702. PubMed ID: 38093484
[TBL] [Abstract][Full Text] [Related]
10. Expert survey on real-world data utilization and real-world evidence generation for regulatory decision-making in drug lifecycle in Korea.
Lee H; Ahn HS; Kwon S; Kang HY; Han E
Clin Transl Sci; 2024 Apr; 17(4):e13801. PubMed ID: 38629484
[TBL] [Abstract][Full Text] [Related]
11. Real-World Evidence: A Primer.
Dang A
Pharmaceut Med; 2023 Jan; 37(1):25-36. PubMed ID: 36604368
[TBL] [Abstract][Full Text] [Related]
12. Tactical Considerations for Designing Real-World Studies: Fit-for-Purpose Designs That Bridge Research and Practice.
Dreyer NA; Mack CD
Pragmat Obs Res; 2023; 14():101-110. PubMed ID: 37786592
[TBL] [Abstract][Full Text] [Related]
13. Dasatinib: from treatment of imatinib-resistant or -intolerant patients with chronic myeloid leukemia to treatment of patients with newly diagnosed chronic phase chronic myeloid leukemia.
Abbott BL
Clin Ther; 2012 Feb; 34(2):272-81. PubMed ID: 22285209
[TBL] [Abstract][Full Text] [Related]
14. Nonrandomized Real-World Evidence to Support Regulatory Decision Making: Process for a Randomized Trial Replication Project.
Franklin JM; Pawar A; Martin D; Glynn RJ; Levenson M; Temple R; Schneeweiss S
Clin Pharmacol Ther; 2020 Apr; 107(4):817-826. PubMed ID: 31541454
[TBL] [Abstract][Full Text] [Related]
15. A systematic review of real-world evidence (RWE) supportive of new drug and biologic license application approvals in rare diseases.
Vaghela S; Tanni KA; Banerjee G; Sikirica V
Orphanet J Rare Dis; 2024 Mar; 19(1):117. PubMed ID: 38475874
[TBL] [Abstract][Full Text] [Related]
16. Real-world data for health technology assessment for reimbursement decisions in Asia: current landscape and a way forward.
Lou J; Kc S; Toh KY; Dabak S; Adler A; Ahn J; Bayani DBS; Chan K; Choiphel D; Chua B; Genuino AJ; Guerrero AM; Kearney B; Lin LW; Liu Y; Nakamura R; Pearce F; Prinja S; Pwu RF; Shafie AA; Sui B; Suwantika A; Teerawattananon Y; Tunis S; Wu HM; Zalcberg J; Zhao K; Isaranuwatchai W; Wee HL
Int J Technol Assess Health Care; 2020 Oct; 36(5):474-480. PubMed ID: 32928330
[TBL] [Abstract][Full Text] [Related]
17. The Use of Real-World Evidence and Data in Clinical Research and Postapproval Safety Studies.
Lamberti MJ; Kubick W; Awatin J; McCormick J; Carroll J; Getz K
Ther Innov Regul Sci; 2018 Nov; 52(6):778-783. PubMed ID: 29714579
[TBL] [Abstract][Full Text] [Related]
18. Replication of Randomized, Controlled Trials Using Real-World Data: What Could Go Wrong?
Thompson D
Value Health; 2021 Jan; 24(1):112-115. PubMed ID: 33431143
[TBL] [Abstract][Full Text] [Related]
19. Integrating Real-World Evidence in the Regulatory Decision-Making Process: A Systematic Analysis of Experiences in the US, EU, and China Using a Logic Model.
Li M; Chen S; Lai Y; Liang Z; Wang J; Shi J; Lin H; Yao D; Hu H; Ung COL
Front Med (Lausanne); 2021; 8():669509. PubMed ID: 34136505
[TBL] [Abstract][Full Text] [Related]
20. Current Status, Challenges, and Future Perspectives of Real-World Data and Real-World Evidence in Japan.
Hiramatsu K; Barrett A; Miyata Y;
Drugs Real World Outcomes; 2021 Dec; 8(4):459-480. PubMed ID: 34148219
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
